ProAir HFA is one of Teva's important branded products.
The Israeli drug developer will pay $67.5 million for Movantik, which treats opioid-induced constipation.
Enlivex Therapeutics exploited yesterday's rise in its share price to raise $8 million.
The round was led by Flerie Invest AB, Oriella Limited, Hadasit Bio-Holdings, Pavilion Capital, and Mirae Asset Venture Investment.
The ArmonAir Digihaler is for the treatment of asthma in patients 12 years and older.
The company raised $50 million six months ago from its existing shareholders, and has now raised a total of $105 million.
Enlivex Therapeutics is increasing production of Allocetra, for treating patients with multisystem failure.
The Israeli economy will be hit hard by the growing effects of the coronavirus, even if the illness is successfully kept out of the country, economists warn.
Teva had 3,961 employees in Israel at the end of 2019, a reduction of 2,284 in two years, including 932 in 2019.
The rapid spread of coronavirus COVID-19 in South Korea led the Israeli authorities to send a Korean Air plane and its 200 Korean passengers back to Seoul yesterday evening.
Israeli drug discovery company Compugen is conducting three cancer treatment trials this year, two of them with Bristol-Myers Squibb.
Inomec will become Integer's Israel development and sales center.
Kare Schultz told Teva's annual press conference that streamlining and optimization won't be enough to get the company back to substantial growth.
The price at which the company is being sold is 97% lower than the price at which trading in the share began in 2007.
Global life science investment group Ally Bridge Group has invested $70 million in two Israeli companies.
The Rehovot-based company is leveraging its proprietary Selective T cell Redirection (STR) platform to develop targeted anticancer immunotherapies.
The Israel Innovation Authority has granted GE NIS 50 million to expand its Rehovot center.
A court ordered Teva to restore the Copaxone rights for treatment of diseases other than multiple sclerosis to Proneuron, but the patent has expired, rendering the rights useless.
However, Berkshire Hathaway still has a loss on paper on its investment in Teva of about $230 million.
Ben Gurion University researcher Dr. Tomer Hertz says flu jabs, like vaccinations against childhood diseases, are a social act that helps prevent infecting others.